These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8354063)

  • 21. Dialysis membrane biocompatibility: effects on cellular elements.
    Coli L; De Sanctis LB; Feliciangeli G; Iannelli S; Scolari MP; Todeschini P; Tumietto F; Costigliola P; Chiodo F
    Nephrol Dial Transplant; 1995; 10 Suppl 10():27-32. PubMed ID: 8825429
    [No Abstract]   [Full Text] [Related]  

  • 22. Approach to dialysis biocompatibility: evaluation through in vivo investigation of lymphocyte biology. A technical note.
    Stefoni S; Feliciangeli G; Nanni Costa A; Coli L; Cianciolo G; De Sanctis LB; Buscaroli A; Iannelli S; Mosconi G; Bonomini V
    Contrib Nephrol; 1993; 103():65-75. PubMed ID: 8354064
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombocytopenia associated with use of a biocompatible hemodialysis membrane: a case report.
    Post JB
    Am J Kidney Dis; 2010 Jun; 55(6):e25-8. PubMed ID: 20110145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dialysis fluid and water: their roles in biocompatibility.
    Berland Y; Brunet P; Ragon A; Reynier JP
    Nephrol Dial Transplant; 1995; 10 Suppl 10():45-7. PubMed ID: 8825432
    [No Abstract]   [Full Text] [Related]  

  • 25. Leukocyte-derived mediators and biocompatibility.
    Tetta C; Segoloni G; Mariano F; Montrucchio G; Turello E; Camussi G
    Nephrol Dial Transplant; 1991; 6 Suppl 2():24-30. PubMed ID: 1866064
    [No Abstract]   [Full Text] [Related]  

  • 26. The role of platelet-activating factor in the haemoincompatibility of haemodialytic treatments.
    Tetta C; Wratten M; Cristol JP; Tarchini R; Bosc JY; Canaud B; Camussi G
    Int J Artif Organs; 1998 Nov; 21(11):693-8. PubMed ID: 9894743
    [No Abstract]   [Full Text] [Related]  

  • 27. Platelet and leucocyte behaviour during haemodialysis.
    Hoenich NA
    Contrib Nephrol; 1999; 125():120-32. PubMed ID: 9895436
    [No Abstract]   [Full Text] [Related]  

  • 28. [Criteria of the biocompatibility of the membranes used in dialysis].
    Stratta P; Canavese C; Segoloni GP; Dogliani M; Racca M; Coppo R; Vercellone A
    Minerva Nefrol; 1981; 28(2):109-11. PubMed ID: 6457263
    [No Abstract]   [Full Text] [Related]  

  • 29. Adherence of blood cells to dialyzer membranes as a measure of biocompatibility.
    Kjellstrand P; Okmark P; Odselius R; Thysell H; Riede G; Holmquist B
    Int J Artif Organs; 1991 Nov; 14(11):698-702. PubMed ID: 1757156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An introduction to biocompatibility.
    Ringoir S; Vanholder R
    Artif Organs; 1986 Feb; 10(1):20-7. PubMed ID: 3516125
    [No Abstract]   [Full Text] [Related]  

  • 31. Biocompatibility of different hemodialysis membranes: activation of complement and leukopenia.
    Wegmüller E; Montandon A; Nydegger U; Descoeudres C
    Int J Artif Organs; 1986 Mar; 9(2):85-92. PubMed ID: 3699914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: an appraisal of the evidence.
    Churchill DN
    Nephrol Dial Transplant; 1995; 10 Suppl 10():52-6. PubMed ID: 8825434
    [No Abstract]   [Full Text] [Related]  

  • 33. Biocompatibility of membranes used in the treatment of renal failure.
    Hoenich NA; Woffindin C; Mathews JN; Vienken J
    Biomaterials; 1995 May; 16(8):587-92. PubMed ID: 7548608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical importance of biocompatibility and its effect on haemodialysis treatment.
    Opatrný K
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v41-4. PubMed ID: 12817068
    [No Abstract]   [Full Text] [Related]  

  • 35. Biocompatibility criteria in hemodialysis.
    Cordonnier DJ; Forêt M
    Contrib Nephrol; 1989; 71():30-5. PubMed ID: 2680263
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical implications of hemodialysis membrane biocompatibility.
    Hakim RM
    Kidney Int; 1993 Sep; 44(3):484-94. PubMed ID: 8231020
    [No Abstract]   [Full Text] [Related]  

  • 37. Heparin-like polymer surfaces: control of coagulation and complement activation by insoluble functionalized polymers.
    Labarre DJ
    Int J Artif Organs; 1990 Oct; 13(10):651-7. PubMed ID: 2254040
    [No Abstract]   [Full Text] [Related]  

  • 38. AN69-ST membrane, a useful option in two cases of severe dialysis reactions.
    Cerqueira A; Martins PA; Carvalho BA; Vasconcelos MP
    Clin Nephrol; 2015 Feb; 83(2):100-3. PubMed ID: 25208312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biocompatibility of various dialysis membranes as assessed by coagulation assay.
    Gasparotto ML; Bertoli M; Vertolli U; Ruffatti A; Stoppa ML; Di Landro D; Romagnoli GF
    Contrib Nephrol; 1984; 37():96-100. PubMed ID: 6713885
    [No Abstract]   [Full Text] [Related]  

  • 40. Are there long-term clinical consequences related to membrane biocompatibility?
    van Ypersele de Strihou C; De Meyer M
    Contrib Nephrol; 1989; 71():36-9. PubMed ID: 2680264
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.